Zacks Research Issues Optimistic Estimate for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities researchers at Zacks Research increased their Q1 2026 earnings estimates for Theravance Biopharma in a research note issued to investors on Thursday, April 9th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn $0.01 per share for the quarter, up from their previous estimate of ($0.15). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.62 EPS, FY2026 earnings at $0.80 EPS, Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at $0.43 EPS and FY2027 earnings at $0.28 EPS.

Other equities analysts also recently issued reports about the company. TD Cowen raised their price target on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a report on Monday, March 23rd. B. Riley Financial raised their price target on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, April 7th. BTIG Research restated a “buy” rating and set a $21.00 price target on shares of Theravance Biopharma in a report on Friday, March 20th. Weiss Ratings downgraded Theravance Biopharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday. Finally, HC Wainwright raised their price target on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.83.

Theravance Biopharma Stock Up 0.6%

Shares of TBPH stock opened at $16.60 on Tuesday. The stock has a fifty day moving average of $16.62 and a 200 day moving average of $17.11. Theravance Biopharma has a 52 week low of $8.33 and a 52 week high of $21.03. The firm has a market capitalization of $854.73 million, a price-to-earnings ratio of 8.18 and a beta of 0.17.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds have recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Theravance Biopharma during the 3rd quarter worth approximately $10,611,000. Assenagon Asset Management S.A. raised its holdings in shares of Theravance Biopharma by 1,629.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock worth $6,055,000 after acquiring an additional 390,735 shares in the last quarter. Pacer Advisors Inc. purchased a new stake in shares of Theravance Biopharma during the 4th quarter worth approximately $6,342,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Theravance Biopharma during the 3rd quarter worth approximately $4,536,000. Finally, Janus Henderson Group PLC raised its holdings in shares of Theravance Biopharma by 214.8% during the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock worth $7,493,000 after acquiring an additional 273,288 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by insiders.

Trending Headlines about Theravance Biopharma

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Zacks Research sharply raised multi-quarter and full‑year EPS forecasts for TBPH (notably FY2026 raised to $0.80 from a prior loss estimate and FY2027 to $0.28), and reiterated a “Strong-Buy” view — an across‑the‑board upgrade to near‑term profitability that can support higher valuation and buying interest. Zacks Research coverage summary
• Positive Sentiment: Wall Street Zen upgraded TBPH to “Strong‑Buy”, adding independent positive analyst sentiment which can boost investor confidence and momentum. Theravance Biopharma Rating Increased to Strong-Buy at Wall Street Zen
• Negative Sentiment: Pomerantz LLP issued an investor alert saying it is investigating claims on behalf of Theravance investors — a potential securities litigation risk that can increase uncertainty, legal costs and volatility for the stock. Pomerantz investor alert

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.